Focus Partners Advisor Solutions LLC Boosts Position in AbbVie Inc. $ABBV

Focus Partners Advisor Solutions LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 23.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,485 shares of the company's stock after purchasing an additional 7,576 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in AbbVie were worth $9,936,000 as of its most recent SEC filing.

• MarketBeat Week in Review – 08/03 - 08/07

Several other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. raised its position in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Ieq Capital LLC raised its position in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock valued at $22,281,000 after purchasing an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its stake in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock worth $210,685,000 after purchasing an additional 612,702 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Billionaire investor Ken Griffin increased his AbbVie position by 547% in the second quarter, highlighting institutional confidence in the company’s high dividend yield and relatively defensive business profile. Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2
• Positive Sentiment: AbbVie’s immunology franchise remains a key growth anchor, while newer medicines and its oncology pipeline are helping diversify the company beyond Humira and support its longer-term outlook. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Recent quarterly results exceeded analyst expectations, with revenue up 10.2% year over year and earnings modestly ahead of consensus. Management’s third-quarter earnings outlook also points to continued operating momentum.
• Neutral Sentiment: Analysts see AbbVie and Eli Lilly as offering different combinations of growth, pipeline potential and risk; the comparison reinforces that AbbVie is viewed more as a dividend and established-product investment than a high-growth pharmaceutical story. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Valuation is the main near-term concern. After its strong run, AbbVie trades at an elevated earnings multiple, leaving less room for disappointment if growth slows or pipeline investments take longer to pay off. Has AbbVie Stock Become Too Expensive to Buy?
• Negative Sentiment: Second-quarter oncology sales declined 2.4%, primarily because of falling Imbruvica revenue. Growth from Venclexta and newer products only partially offset that pressure, raising concerns about the pace of AbbVie’s portfolio transition. How Did ABBV’s Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

Insider Activity

• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

AbbVie Stock Down 1.0%

Shares of NYSE:ABBV opened at $263.08 on Thursday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a 50-day moving average price of $251.04 and a 200 day moving average price of $228.43. The company has a market cap of $464.81 billion, a P/E ratio of 74.32, a PEG ratio of 0.88 and a beta of 0.30.

• AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie's dividend payout ratio is 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, April 30th. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. UBS Group upped their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Finally, Guggenheim increased their price objective on AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $275.95.

View Our Latest Stock Analysis on AbbVie

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Featured Articles

• Five stocks we like better than AbbVie
• Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here